AKI vs CKD vs Acute-on-Chronic

A creatinine of 2.4 mg/dL means something very different depending on context. In a patient whose baseline creatinine was 0.9 mg/dL, it represents acute kidney injury — a potentially reversible process that requires urgent evaluation and treatment. In a patient whose creatinine has been 2.2–2.5 mg/dL for two years, it represents chronic kidney disease — a stable, chronic condition that requires long-term management. In a patient with CKD stage 3 whose creatinine has risen from 1.8 to 2.4 mg/dL over the past week, it represents acute-on-chronic kidney injury — a superimposed acute insult on a background of chronic disease, with a worse prognosis than either alone.

The distinction between AKI, CKD, and acute-on-chronic kidney injury drives the urgency of evaluation, the choice of interventions, the medications that must be held or dose-adjusted, and the prognosis. Without prior creatinine values, the distinction is impossible — and clinical decisions made without this context are frequently incorrect.

AKI is defined by the KDIGO criteria as a rise in serum creatinine of 0.3 mg/dL or more within 48 hours, or a 1.5-fold or greater rise from baseline within 7 days, or urine output below 0.5 mL/kg/hour for 6 or more hours. These criteria emphasize trajectory — not a single absolute value.

AKI is staged 1 through 3 based on the magnitude of creatinine rise or the degree of oliguria. Stage 3 includes patients requiring renal replacement therapy regardless of creatinine level. Staging guides the urgency of nephrology consultation and the intensity of monitoring.

The causes of AKI are traditionally divided into pre-renal (reduced renal perfusion), intrinsic renal (direct kidney damage), and post-renal (obstruction). Pre-renal AKI — from volume depletion, heart failure, hepatorenal syndrome, or medications that reduce renal perfusion (NSAIDs, ACE inhibitors in the setting of volume depletion) — is the most common cause and is often reversible with appropriate treatment. Intrinsic renal AKI includes acute tubular necrosis (the most common intrinsic cause), acute interstitial nephritis, glomerulonephritis, and vascular causes. Post-renal AKI from obstruction is important to exclude early because it is often reversible with relief of the obstruction.

CKD is defined as abnormalities of kidney structure or function present for more than 3 months. The definition requires chronicity — a single elevated creatinine or a single abnormal finding does not establish CKD. The diagnosis requires either repeated measurements showing persistent abnormality over at least 3 months, or structural evidence of kidney damage (imaging, biopsy) with an implied duration.

CKD is staged by GFR category (G1–G5) and albuminuria category (A1–A3). The combination of GFR and albuminuria categories determines the risk of CKD progression and cardiovascular events. A patient with eGFR 55 mL/min/1.73m² and urine albumin-to-creatinine ratio of 350 mg/g is at much higher risk than a patient with the same eGFR and a ratio of 15 mg/g.

CKD does not cause symptoms until late stages (G4–G5). Most patients with CKD stages 1–3 are asymptomatic and are identified incidentally on routine labs. The absence of symptoms does not exclude significant CKD — and the absence of symptoms in a patient with newly discovered elevated creatinine does not mean the finding can be deferred.

Acute-on-chronic kidney injury occurs when an acute insult is superimposed on pre-existing CKD. It is not simply "worse CKD" — it is a distinct clinical entity with a worse prognosis than either AKI or CKD alone. The superimposed acute insult may be reversible, but the underlying CKD limits the degree of recovery. Full return to prior baseline function is often not achievable.

The acute component of acute-on-chronic kidney injury has the same causes as AKI in patients without CKD — volume depletion, nephrotoxins, obstruction, infection, contrast exposure, and medications. However, patients with CKD are more vulnerable to acute insults because their reduced nephron mass provides less reserve. A degree of volume depletion that would cause only mild, transient creatinine elevation in a patient with normal kidneys may cause significant AKI in a patient with CKD stage 3.

Identifying and treating the acute component is essential — even if full recovery is not expected. Removing nephrotoxins, restoring volume, relieving obstruction, and treating infection can prevent further progression and may allow partial recovery toward the prior CKD baseline.

The first step is always to find prior creatinine values. Electronic medical records, prior lab reports, and primary care records are all potential sources. If no prior values are available, the clinical history — duration of symptoms, prior diagnoses, prior imaging — helps estimate whether the elevation is acute or chronic.

Assess for reversible causes of AKI: volume status (orthostatic vitals, mucous membranes, skin turgor, JVD, edema), medication review (NSAIDs, ACE inhibitors, ARBs, aminoglycosides, contrast, diuretics), urinary obstruction (bladder scan, renal ultrasound), and infection.

Urine studies help differentiate AKI subtypes. Urine sodium, fractional excretion of sodium (FENa), urine osmolality, and urine microscopy are the key tests. A FENa below 1% with concentrated urine suggests pre-renal physiology. Granular casts (muddy brown casts) on urine microscopy suggest acute tubular necrosis. Red blood cell casts suggest glomerulonephritis. However, these tests have important limitations in patients with CKD, diuretic use, or mixed etiologies.

Renal ultrasound is indicated when obstruction is suspected, when CKD is newly diagnosed (to assess kidney size and echogenicity), or when the cause of AKI is unclear. Small, echogenic kidneys suggest chronic disease. Normal-sized kidneys with AKI suggest an acute process.

For AKI: the management priority is identifying and reversing the cause. Volume-depleted pre-renal AKI responds to fluid resuscitation. Obstructive AKI requires relief of the obstruction (urologic consultation, catheter placement). Nephrotoxin-induced AKI requires removal of the offending agent. Intrinsic renal causes (glomerulonephritis, vasculitis, interstitial nephritis) may require specific immunosuppressive therapy and nephrology involvement.

For CKD: management focuses on slowing progression and managing complications. ACE inhibitors or ARBs are first-line for CKD with proteinuria — they reduce intraglomerular pressure and slow progression. Blood pressure control (target below 130/80 in most CKD patients), glycemic control in diabetic nephropathy, and avoidance of nephrotoxins are the pillars of CKD management. SGLT2 inhibitors have demonstrated renoprotective effects in CKD with and without diabetes.

CKD complications requiring active management include anemia (erythropoiesis-stimulating agents or iron supplementation), hyperkalemia (dietary restriction, potassium binders), metabolic acidosis (sodium bicarbonate supplementation), secondary hyperparathyroidism (phosphate restriction, vitamin D supplementation), and volume overload (loop diuretics).

For acute-on-chronic: the acute component is managed as AKI — identify and reverse the precipitant. The chronic component requires ongoing CKD management. The key clinical question is whether the patient has returned to their CKD baseline after the acute event, or whether there has been a permanent step-down in function.

Nephrology referral criteria: eGFR below 30 (CKD stage 4) for preparation for renal replacement therapy, AKI requiring dialysis consideration, AKI without a clear cause, rapidly progressive kidney disease (doubling of creatinine over weeks), significant proteinuria (above 300 mg/g), suspected glomerulonephritis or vasculitis, refractory hyperkalemia or metabolic acidosis, and CKD with complex management needs. Earlier referral (eGFR below 45) is appropriate when the trajectory is concerning or the cause is uncertain.